Virtual reality mindfulness for reducing aggression in schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, parallel-group trial compares two doses of a mindfulness-based virtual reality (MBI-VR) program (16 vs. 24 sessions) against a non-immersive distraction control, with participants receiving repeated VR sessions. The study enrolls adults with schizophrenia or schizoaffective disorder who have a history of impulsive aggression and are on stable atypical antipsychotic treatment. Neural target engagement is measured with fMRI focusing on dorsomedial prefrontal cortex (dmPFC) activation during an emotion regulation task, and clinical scales track changes in impulsive aggression. The design also examines whether clinical and neural effects scale with the number of MBI-VR sessions (dose-related relationship).

Why it matters

Who can join: the full rules

Inclusion Criteria:

TRIPP MBI VR and TAU Distraction Groups have the same inclusion criteria. Participants will:

1. Is willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.
2. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.
3. Be on optimized and stable atypical antipsychotic treatment as indicated by no antipsychotic changes in 2 weeks prior to enrollment.
4. Demonstrate documented evidence of good medication adherence for the 2 weeks prior to enrollment, as determined by electronic medication records review and prescriber reported adherence to prescribed schedule as documented in the participant's medical records.
5. Have a history of impulsive aggression as assessed by a score of ≥ 4 on any item on Impulsive Aggression Factor (IA) on the Impulsive- Premeditated Aggression Scale (IPAS; Stanford et al., 2003).
6. Have adequate visual and auditory abilities to complete assessments, see and hear stimuli in the VR
7. Has a primary diagnosis of schizophrenia using the diagnostic criteria for schizophrenia or schizoaffective disorder, as defined in the SCID-5-RV at the Screening Visit.
8. Adult or late adolescent, between 18 and 64 years of age at the time of informed consent.

Exclusion Criteria:

Participants will be excluded if they:

1. Have past head trauma
2. Diagnosed with a neurological disorder
3. Are pregnant or breastfeeding women as evidenced by the participant's medical record.
4. Have unstable medical illness that compromises the safety of the patient
5. Have significant suicidal ideation at screening (as assessed by the Columbia - Suicide Severity Rating Scale (C-SSRS; participant answers "Yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS; Non-suicidal self-injurious behavior is not exclusionary)
6. Are on Electroconvulsive therapy (ECT) within 6 months of the study, participants with metal in their bodies or who have claustrophobia or who do not pass the criteria in NKI's Magnetic Resonance Safety Questionnaire (MRSQ)
7. Score \< 4 on all items on Impulsive Aggression Factor (IA) on the IPAS (Stanford et al., 2003)
8. Have a violent episode requiring seclusion, restraints, or a prn within the week before screening
9. Evidence of suboptimal medication adherence in the 2 weeks prior to enrollment, as determined by electronic medication records review, and demonstrated by prescriber reported non- adherence to prescribed schedule. Suboptimal adherence includes missed doses (two of more missed doses within the past 2 weeks) or plasma levels indicating that the participant is not receiving the intended therapeutic dose.

Where it's running

• Manhattan Psychiatric Center
  New York, New York, United States Recruiting
• NewYork-Presbyterian/Weill Cornell Medical Center Westchester Division
  White Plains, New York, United States Recruiting

Study contacts

• Principal investigator: Anzalee Khan, PhD — Nathan Kline Institute for Psychiatric Research
• Study coordinator: Anzalee Khan, PhD
• Email: anzalee.khan@nki.rfmh.org
• Phone: 646-766-5876

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Just-in-Time Coping Prompts for College Students

  We’re testing whether sending brief coping tips at moments of emotional shift can influence how college students react online, drink, or eat when feelings spike.

  Recruiting University of Florida · Gainesville, Florida · NCT07789314

• Momentary Coping Prompts and Hair Steroids in College Students

  This trial tests whether sending brief coping prompts at moments of emotional volatility helps college students respond to emotions, while collecting hair samples to see if long-term stress hormones relate to those responses.

  Recruiting University of Florida · Gainesville, Florida · NCT07782398

• Combination of Deferiprone and N-Acetylcysteine for Negative Symptoms in Schizophrenia

  This study tests whether adding deferiprone and NAC to the usual antipsychotic treatment can help people with schizophrenia or schizoaffective disorder who have prominent negative symptoms.

  Recruiting Phase 2 Hadassah Medical Organization · Jerusalem and 1 other locations · NCT07759895

• Digital Therapeutics for Social Cognition in Schizophrenia Spectrum Disorder

  A smartphone-based digital therapy called AffectUs is being tested to see if it can help people with schizophrenia or schizoaffective disorder improve social cognition, alongside their usual treatment.

  Recruiting Samsung Medical Center · Seoul · NCT07755605

• Brain-derived miRNA biomarkers in first-episode psychosis

  Researchers will test whether specific brain-derived microRNAs in blood can help identify schizophrenia early and track treatment in people with first-episode psychosis on aripiprazole or risperidone.

  Recruiting Northwell Health · Glen Oaks, New York · NCT07703670

• dACC-targeted temporal interference for negative symptoms in schizophrenia

  This trial tests whether a non-invasive brain stimulation method called temporal interference stimulation, aimed at the dACC, can help with negative symptoms and cognitive difficulties in people with schizophrenia.

  Recruiting Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Shanghai · NCT07658898

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.